• Home
  1. Home
  2. Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma
Scientific article
English

Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma

ContributorsKawahara, Toshiyasu; Toso, Christianorcid; Yamaguchi, Keisuke; Cader, Sonia; Douglas, Donna N; Nourbakhsh, Mahra; Lewis, Jamie T; Churchill, Thomas A; Yagita, Hideo; Kneteman, Norman M
Published inLiver international, vol. 33, no. 9, p. 1441-1448
Publication date2013
Abstract

Despite careful patient selection, hepatocellular carcinoma (HCC) recurs in 10-20% of cases after liver transplantation, and the use of potent adjuvant anticancer drugs would be welcome. The aim of this study was to evaluate the efficiency of a combined therapy of rapamycin (sirolimus) and anti-death receptor (DR)5 monoclonal antibody (mAb) on HCC.

Affiliation entities
Research groups
Citation (ISO format)
KAWAHARA, Toshiyasu et al. Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma. In: Liver international, 2013, vol. 33, n° 9, p. 1441–1448. doi: 10.1111/liv.12275
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Journal ISSN1478-3223
676views
0downloads

Technical informations

Creation16/09/2013 13:41:00
First validation16/09/2013 13:41:00
Update13/10/2025 23:18:03
Status update14/03/2023 20:37:26
Last indexation04/02/2026 14:47:28
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack